BRIGHT MINDS BIOSCIENCES INC.

Bright Minds' PWS Program

Individuals with PWS have reduced levels of functional 5-HT2C receptors, which are central regulators of appetite, satiety, and behavior. Bright Minds is developing highly selective, Gq-biased 5-HT2C agonists designed to restore signaling through this pathway while avoiding the receptor desensitization and 5-HT2B-related cardiac liabilities that limited earlier serotonergic agents.

BMB-101 is being evaluated in NOVA, a randomized, double-blind, placebo-controlled Phase 2a study assessing the effect of BMB-101 on hyperphagia (primary endpoint: change from baseline in the Hyperphagia Questionnaire for Clinical Trials, HQ-CT), PWS-associated behaviors, and safety and tolerability over a 16-week treatment period, with an optional open-label extension.

In November 2025, the Company expanded its Scientific Advisory Board with four global PWS experts, including Theresa V. Strong, PhD, a founding member of FPWR and its Director of Research Programs; Jennifer L. Miller, MD, University of Florida; Elizabeth Roof, H.S.P., M.A., Vanderbilt University; and Tania Markovic, MBBS PhD FRACP, Royal Prince Alfred Hospital, Sydney.